Skip to main content
IEX $240.39 +0.61%
IEX logo

IEX · Idex Corp /De/

Track IEX — free
$240.39 +1.45 (+0.61%) At close · Aug 17
Market Cap
$17.72B
Shares
73.72M
All earnings calls

Earnings call · FY2026 Q2

Q2 2026 IDEX Earnings Conference Call

Q2 2026 IDEX Earnings Conference Call

Concluded Jul 29, 2026 Audio replay
Jul 29, 2026 1:03:36 72 turns
Period
FY2026 Q2
Runtime
1:03:36
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

IDEX delivered Q2 results above guidance with 5% organic sales growth, record orders over $1 billion (+28% organic), and raised full-year 2026 organic growth (to 5-6%) and adjusted EPS (to $8.70-$8.85) guidance. HST led with 47% organic order growth driven by data center, semiconductor, and space and defense demand.

Health & Science Technology (HST) segment strength 61 Order growth and backlog visibility 29 Fluid Metering & Technology (FMT) segment 25 Margin expansion and 80-20 execution 23 IEPA tariff refunds and customer rebates 13 AI-driven end markets demand 10

Management tone

Confident

Net tone +78 · low hedging

Grounding quotes
  • “IDEX delivered strong second quarter results”
  • “Organic sales grew 5%, adjusted EBITDA margin expanded 70 basis points year over year to 28.1%, and adjusted EPS grew 12% to $2.32. These results exceeded our expectations”
  • “feel really good about the future path there”
  • “Very, very encouraged”

Forward guidance

4 guided metrics

Management's latest ranges and targets are included below.

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue $920.60M +6.4% YoY
Diluted EPS $1.93 +10.9% YoY
Gross margin 46.4% +1.1 pp YoY
Net income $143.40M +9% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Q2 organic sales grew 5% and adjusted EPS of $2.32 exceeded guidance range of $2.07-$2.12
  • Record orders of over $1 billion grew 28% organically, led by HST at 47%
  • Raised full-year 2026 organic growth guidance to 5-6% from 3-4%
  • Raised full-year 2026 adjusted EPS guidance to $8.70-$8.85 from $8.35-$8.55
  • Adjusted EBITDA margin expanded 70 bps to 28.1% with strong HST flow-through
  • Strong demand in advantaged markets with data center, semiconductor, and space and defense now over a third of HST revenue

Risks & pressure points

  • FSDP organic sales declined 1% in Q2
  • FMT organic sales grew only 1% in Q2
  • Tariff refund-related customer rebates reduced Q2 organic sales growth by 2%

Key moments

Jump directly to management's words in the synchronized transcript.

Forward guidance

From the 8-K filed Jul 29, 2026.

Metric Guided
Organic sales
Full year 2026
5% – 6%
Adjusted diluted EPS
Full year 2026
$8.70 – $8.85
Adjusted diluted EPS
Third quarter 2026
$2.20 – $2.25
Organic sales
Third quarter 2026
5% – 7%

Quarter detail

How the reported period landed and where the business moved.

Revenue · segments

Health and Science Technologies$414.00M +13.8% YoY
Fluid and Metering Technologies$316.70M +2% YoY
Fire and Safety Diversified Products$189.90M -0.6% YoY

Capital returned

Buybacks · derived
$77.10M
Full-screen source Call document